Background: Cancer nanotherapy integrate efficacious molecules that otherwise
could not be used because of their high toxicity and exploit multiple mechanisms of
actions (e.g. multifunctional gels, functional polymers, hybrid nanoparticles). The aim of
this review is to contemplate the designed and developed nanoparticulate systems that
exhibit a benefit in cancer nanotherapy strongly related with the properties of the nanoplatforms
Method: Systemic search and review of papers regarding cancer nanotherapy took place
via MedLine and abstract presentations of international conferences.
Results: The recent advances in the development of self-assembled structures of lipids-
(i.e. liposomes, niosomes, etc.) and of polymers- (micelles, polymersomes, dendrimers,
polymeric nanoparticles, hydrogels, etc.) as well as clinical perspectives will be discussed
on the basis of pharmaceutical nanotechnology considerations, and on their in vitro and in
vivo evaluation. Chimeric/Mixed nanoplatforms that are composed at least of two different
in nature biomaterials (i.e. phospholipids and polymers) can be considered as new
technological outcomes in cancer nanotherapy that could be able to deliver anticancer
drugs to specific tissues.
Conclusion: They can improve the pharmacokinetics/pharmacodynamics behavior of antitumor
molecules, affect their total bioavailability and provide innovative delivery behavior
due to their nanotechnological profile.